Gynecologic Cancers

Kimberly Halla, NP, explains the staging of endometrial cancer and the standards for biomarker testing at her institution.

Kimberly A. Spickes, CNP, gives an overview of the typical symptoms women with endometrial cancer present with, discusses how these symptoms are similar and different from those seen with other gynecologic malignancies, and reviews risk factors for endometrial cancer.

Increasing the duration of bevacizumab treatment did not improve progression-free survival for patients with ovarian cancer.

Mirvetuximab soravtansine-gynx, an antibody drug conjugate, has received accelerated approval for platinum-resistant ovarian cancer. The prescribing label comes with warnings for visual toxicities, pneumonitis, and peripheral neuropathy.

During the 40th Annual Chemotherapy Foundation Symposium, Eirwen M. Miller, MD, evaluated the safety and efficacy profiles of different PARP inhibitor therapies for patients with advanced ovarian cancer.

Immunotherapy has changed the face of cancer treatment, but requires appropriate irAE management to reach full potential.

Olaparib is an oral drug manufactured in 150-mg and 100-mg tablets. Olaparib is taken by mouth, twice daily. It can be taken without or without food.

Patients with heavily pretreated clear cell gynecologic cancer achieved encouraging responses with single-agent pembrolizumab.

An analysis of patient-reported outcomes showed that patients with advanced ovarian cancer experienced fewer abdominal or gastrointestinal toxicities with mirvetuximab soravtansine than with chemotherapy.

A combination of the aromatase inhibitor letrozole and the CDK4/6 inhibitor abemaciclib may help patients with recurrent estrogen receptor–positive endometrial cancer achieve responses.

Neratinib was associated with a clinical benefit rate of 45.5% among patients with metastatic or recurrent HER2-mutated cervical cancer.

Structured preceptorships promote competence, confidence, and job satisfaction in new oncology nurse practitioners.

Following potential safety concerns with 3 PARP inhibitors, manufactures have voluntarily elected to withdraw the indications for patients with heavily pretreated patients with BRCA-mutated ovarian cancer.

Selpercatinib was approved by the FDA for RET fusion–positive non–small cell lung cancer and locally advanced or metastatic RET fusion–positive solid tumors.

Intense-modulated therapy was associated with less patient-reported toxicities than conventional radiotherapy and demonstrated a comparable efficacy profile.

Real-world data from a retrospective study showed that pembrolizumab combined with the anti-VEGF agent bevacizumab plus oral metronomic cyclophosphamide displayed minimal toxicity in a significant number of patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.

In the phase 1 SURPASS trial, 72% of patients with solid tumors developed any-grade cytokine release syndrome following an infusion of ADP-A2M4CD8. The median time to resolution was 5 days.

Women with ovarian cancer who received 2 years of maintenance therapy with olaparib experienced a 45% reduction in risk of death, according to a 7-year follow-up.

Hearing loss for cancer survivors is largely underreported, but once identified, is easily treatable, according to Christine Miaskowski, PhD, RN.

Paula Anastasia, RN, MN, AOCN, discusses the value of germline testing and the role of maintenance PARP inhibitor therapy in optimized ovarian cancer treatment.

Chinese patients with newly diagnosed advanced ovarian cancer whose disease responsed to first-line chemotherapy experienced significantly improved progression-free survival with niraparib.

In early-stage cancers, ctDNA has a role in screening, neoadjuvant monitoring, identification of molecular residual disease (MRD), molecular relapse monitoring, and early assessment of treatment response.

Lidia Schapira, MD, FASCO, discusses the importance of rigorous baseline measurement in improving the assessment and management of distressful cancer symptoms.

Mirvetuximab soravtansine (IMGN853) has been granted priority review by the FDA for the treatment of patients with FRα-high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Patients receiving bevacizumab plus olaparib to treat newly diagnosed ovarian cancer experienced significantly longer time without signs of toxicity compared with placebo.

The FDA approval of dabrafenib plus trametinib for BRAF V600E–mutated unresectable or metastatic solid tumors highlights a potential need for routine BRAF testing in clinical practice, experts say.

A real-world analysis showed that the proportion of women with ovarian cancer who required dose modifications or treatment discontinuations while receiving PARP inhibitors differed significantly between olaparib, niraparib, and rucaparib.

Ovarian clear cell carcinoma is a rare histological type of epithelial ovarian cancer that is typically resistant to chemotherapy and is historically associated with poor prognosis for patients.

Atezolizumab in conjunction with VB10.16, the first off-the-shelf therapeutic cancer vaccine, elicited encouraging responses in pretreated patients with HPV16-positive advanced cervical cancer.

New research suggests that olaparib treatment interruption or dosage reduction is not linked with inferior survival outcomes in patients with BRCA1/2–mutated, platinum-sensitive, recurrent ovarian cancer.